Payment of Directors' Fees in Shares
12 January2010, London, UK, and Cambridge, MA: Cancer drug developer Antisoma
plc (LSE: ASM; USOTC: ATSMY) today announces that three Non-Executive Directors
of Antisoma have taken all or part of their fees for the quarter ended 31
December 2009 in ordinary shares pursuant to resolutions of the Board of
Directors dated 14 September 2004 and subsequently.
The new ordinary shares were issued at a price of 33 pence per share, this being
the mid-market closing price on the last trading day of the quarter (31 December
2009). The relevant Directors have agreed not to dispose of the shares allotted
for a minimum period of one year.
The allotment and total holdings following this allotment are shown below.
Allotted Total Percentage of issued
Director 12 Jan 10 holding ordinary shares
Michael Lewis 26,515 180,778 0.03%
Barry Price 17,945 811,022 0.13%
Birgit Stattin-Norinder 6,629 6,629 0.001%
Application will be made to the London Stock Exchange and the UK Listing
Authority for the admission of the new ordinary shares of 1p each. The total
number of ordinary shares in the Company in issue and admitted to the Official
List following the above allotments will be626,045,293.
The new ordinary shares will rankpari passu with the Company's existing ordinary
shares.
Enquiries:
Chris Elston
Antisoma plc
+44 (0)20 3249 2145
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has operations
in the UK and the US. Please visitwww.antisoma.com <http://www.antisoma.com/>
for further information about Antisoma.
[HUG#1372789]